Europe Electronic Clinical Outcome Assessment (eCOA) Market - Industry Trends and Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION 11

• 1.1 OBJECTIVES OF THE STUDY 11
• 1.2 MARKET DEFINITION 11
• 1.3 OVERVIEW OF THE EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET 12
• 1.4 LIMITATIONS 13
• 1.5 MARKETS COVERED 13

2 MARKET SEGMENTATION 15

• 2.1 MARKETS COVERED 15
• 2.2 GEOGRAPHICAL SCOPE 16
• 2.3 YEARS CONSIDERED FOR THE STUDY 17
• 2.4 CURRENCY AND PRICING 17
• 2.5 DBMR TRIPOD DATA VALIDATION MODEL 18
• 2.6 MULTIVARIATE MODELLING 21
• 2.7 PRODUCTS LIFELINE CURVE 21
• 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 22
• 2.9 DBMR MARKET POSITION GRID 23
• 2.10 MARKET END USER COVERAGE GRID 24
• 2.11 VENDOR SHARE ANALYSIS 25
• 2.12 SECONDARY SOURCES 26
• 2.13 ASSUMPTIONS 26

3 EXECUTIVE SUMMARY 27

4 PREMIUM INSIGHTS 30

• 4.1 PESTEL ANALYSIS 31
• 4.2 PORTER'S FIVE FORCES 32

5 REGULATORY FRAMEWORK 33

• 5.1 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) 33
• 5.2 REGULATORY FRAMEWORK FOR ECOA 33
• 5.3 ICH E6 (R2) 33
• 5.4 FDA GUIDANCE 33
• 5.5 EMA GUIDELINES 33
  • 5.5.1 ISO 14155 34
  • 5.5.2 PRIVACY REGULATIONS 34 

6 MARKET OVERVIEW 35

• 6.1 DRIVERS 37
  • 6.1.1 GROWING ACCEPTANCE OF ECOA AMONG CLINICAL RESEARCH PROFESSIONALS 37
  • 6.1.2 PARADIGM SHIFT TOWARDS ELECTRONIC DATA CAPTURING FROM PAPER-BASED PROCEDURES 38
  • 6.1.3 GOVERNMENT INITIATIVES ABOUT THE ADOPTION OF ECLINICAL PLATFORMS 39
• 6.2 RESTRAINTS 39
  • 6.2.1 IMPLEMENTATION OF 'BRING YOUR OWN DEVICE' (BYOD) TECHNOLOGY IN CLINICAL TRIALS 39
  • 6.2.2 LACK OF PROPER HEALTHCARE IT INFRASTRUCTURE IN DEVELOPING COUNTRIES 40
• 6.3 OPPORTUNITIES 42
  • 6.3.1 GROWING ADOPTION OF CLOUD BASED SERVICES 42
  • 6.3.2 RISING NUMBER OF RESEARCH STUDIES FOCUSING ON CLINICAL OUTCOME ASSESSMENTS 42
• 6.4 CHALLENGES 43
  • 6.4.1 DIFFICULTIES ASSOCIATED WITH TRAINING OF RESPONDENTS TO FILL ELECTRONIC QUESTIONNAIRES 43
  • 6.4.2 STREAMLINING OF ECOA SERVICES 43

7 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY TYPE 45

• 7.1 OVERVIEW 46
• 7.2 CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO) 49
• 7.3 PATIENT REPORTED OUTCOME ASSESSMENT (PRO) 49
• 7.4 OBSERVER REPORTED OUTCOME ASSESSMENT (OBSRO) 49
• 7.5 PERFORMANCE OUTCOME ASSESSMENT (PERFO) 49

8 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY MODALITY 50

• 8.1 OVERVIEW 51
• 8.2 SITE-BASED SOLUTIONS 54
• 8.3 WEB SOLUTIONS 54
• 8.4 HANDHELD 54
  • 8.4.1 BRING-YOUR-OWN-DEVICE (BYOD) 54
  • 8.4.2 PROVISIONED DEVICES 54 

9 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY END USER 55

• 9.1 OVERVIEW 56
• 9.2 CONTRACT RESEARCH ORGANIZATIONS (CROS) 59
• 9.3 PHARMACEUTICAL AND BIOTECHNOLOGY FIRMS 59
• 9.4 MEDICAL DEVICE COMPANIES 59
• 9.5 HOSPITALS/HEALTHCARE PROVIDERS 59
• 9.6 CONSULTING SERVICE COMPANIES 59
• 9.7 ACADEMIC & RESEARCH INSTITUTES 59
• 9.8 OTHERS 59

10 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, BY DELIVERY MODE 60

• 10.1 OVERVIEW 61
• 10.2 CLOUD-BASED 64
• 10.3 WEB-HOSTED 64

11 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET BY GEOGRAPHY 65

• 11.1 EUROPE 65
  • 11.1.1 U.K. 65
  • 11.1.2 GERMANY 65
  • 11.1.3 SPAIN 65
  • 11.1.4 FRANCE 65
  • 11.1.5 ITALY 65
  • 11.1.6 SWITZERLAND 65
  • 11.1.7 NETHERLANDS 65
  • 11.1.8 BELGIUM 66
  • 11.1.9 TURKEY 66
  • 11.1.10 RUSSIA 66
  • 11.1.11 REST OF EUROPE 66

12 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET, COMPANY LANDSCAPE 67

• 12.1 COMPANY SHARE ANALYSIS: EUROPE 67

13 SWOT ANALYSIS 68

14 COMPANY PROFILE 69

• 14.1 MEDIDATA 69
  • 14.1.1 COMPANY SNAPSHOT 69
  • 14.1.2 REVENUE ANALYSIS 69
  • 14.1.3 COMPANY SHARE ANALYSIS 70
  • 14.1.4 PRODUCT PORTFOLIO 70
  • 14.1.5 RECENT DEVELOPMENTS 70
• 14.2 CLARIO 71
  • 14.2.1 COMPANY SNAPSHOT 71
  • 14.2.2 COMPANY SHARE ANALYSIS 71
  • 14.2.3 PRODUCT PORTFOLIO 72
  • 14.2.4 RECENT DEVELOPMENT 72
• 14.3 IBM 73
  • 14.3.1 COMPANY SNAPSHOT 73
  • 14.3.2 REVENUE ANALYSIS 73
  • 14.3.3 COMPANY SHARE ANALYSIS 74
  • 14.3.4 PRODUCT PORTFOLIO 74
  • 14.3.5 RECENT DEVELOPMENT 74
• 14.4 SIGNANT HEALTH 75
  • 14.4.1 COMPANY SNAPSHOT 75
  • 14.4.2 COMPANY SHARE ANALYSIS 75
  • 14.4.3 PRODUCT PORTFOLIO 76
  • 14.4.4 RECENT DEVELOPMENTS 76
• 14.5 IQVIA INC, 77
  • 14.5.1 COMPANY SNAPSHOT 77
  • 14.5.2 REVENUE ANALYSIS 77
  • 14.5.3 COMPANY SHARE ANALYSIS 78
  • 14.5.4 PRODUCT PORTFOLIO 78
  • 14.5.5 RECENT DEVELOPMENT 78
• 14.6 ARISEUROPE 79
  • 14.6.1 COMPANY SNAPSHOT 79
  • 14.6.2 PRODUCT PORTFOLIO 79
  • 14.6.3 RECENT DEVELOPMENTS 80
• 14.7 CASTOR 81
  • 14.7.1 COMPANY SNAPSHOT 81
  • 14.7.2 PRODUCT PORTFOLIO 81
  • 14.7.3 RECENT DEVELOPMENTS 81 
• 14.8 CLOUDBYZ 82
  • 14.8.1 COMPANY SNAPSHOT 82
  • 14.8.2 PRODUCT PORTFOLIO 82
  • 14.8.3 RECENT DEVELOPMENT 82
• 14.9 CLINICAL INK. 83
  • 14.9.1 COMPANY SNAPSHOT 83
  • 14.9.2 PRODUCT PORTFOLIO 83
  • 14.9.3 RECENT DEVELOPMENT 83
• 14.10 EVIDENTIQ 84
  • 14.10.1 COMPANY SNAPSHOT 84
  • 14.10.2 PRODUCT PORTFOLIO 84
  • 14.10.3 RECENT DEVELOPMENT 84
• 14.11 FOUNTAYN 85
  • 14.11.1 COMPANY SNAPSHOT 85
  • 14.11.2 PRODUCT PORTFOLIO 85
  • 14.11.3 RECENT DEVELOPMENTS 85
• 14.12 KAYENTIS 86
  • 14.12.1 COMPANY SNAPSHOT 86
  • 14.12.2 PRODUCT PORTFOLIO 86
  • 14.12.3 RECENT DEVELOPMENT 86
• 14.13 RAYLYTIC GMBH 87
  • 14.13.1 COMPANY SNAPSHOT 87
  • 14.13.2 PRODUCT PORTFOLIO 87
  • 14.13.3 RECENT DEVELOPMENTS 87
• 14.14 TRANSPERFECT LIFE SCIENCES LIFE SCIENCES 88
  • 14.14.1 COMPANY SNAPSHOT 88
  • 14.14.2 PRODUCT PORTFOLIO 88
  • 14.14.3 RECENT DEVELOPMENT 88
• 14.15 VITALOGRAPH 89
  • 14.15.1 COMPANY SNAPSHOT 89
  • 14.15.2 PRODUCT PORTFOLIO 89
  • 14.15.3 RECENT DEVELOPMENTS 89
• 14.16 YPRIME LLC. 90
  • 14.16.1 COMPANY SNAPSHOT 90
  • 14.16.2 PRODUCT PORTFOLIO 90
  • 14.16.3 RECENT DEVELOPMENTS 90

15 QUESTIONNAIRE 91

16 RELATED REPORTS 94

LIST OF TABLES

• TABLE 1 COST COMPARISON - PAPER COA TO ECOA 38

LIST OF FIGURES

• FIGURE 1 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: SEGMENTATION 15
• FIGURE 2 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: DATA TRIANGULATION 18
• FIGURE 3 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: DROC ANALYSIS 19
• FIGURE 4 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 20
• FIGURE 5 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: COMPANY RESEARCH ANALYSIS 20
• FIGURE 6 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: INTERVIEW DEMOGRAPHICS 22
• FIGURE 7 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: DBMR MARKET POSITION GRID 23
• FIGURE 8 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: MARKET END USER COVERAGE GRID 24
• FIGURE 9 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: VENDOR SHARE ANALYSIS 25
• FIGURE 10 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: SEGMENTATION 29
• FIGURE 11 GROWING ACCEPTANCE OF ECOA AMONG CLINICAL RESEARCH PROFESSIONALS IS DRIVING THE EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 30
• FIGURE 12 CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO) ARE EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET IN 2020 & 2030 30
• FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET 36
• FIGURE 14 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY TYPE, 2022 46
• FIGURE 15 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 47
• FIGURE 16 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY TYPE, CAGR (2023-2030) 47
• FIGURE 17 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY TYPE, LIFELINE CURVE 48
• FIGURE 18 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY MODALITY, 2022 51
• FIGURE 19 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY MODALITY, 2023-2030 (USD THOUSAND) 52
• FIGURE 20 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY MODALITY, CAGR (2023-2030) 52
• FIGURE 21 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY MODALITY, LIFELINE CURVE 53
• FIGURE 22 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY END USER, 2022 56
• FIGURE 23 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY END USER, 2023-2030 (USD THOUSAND) 57
• FIGURE 24 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY END USER, CAGR (2023-2030) 57
• FIGURE 25 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY END USER, LIFELINE CURVE 58
• FIGURE 26 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY DELIVERY MODE, 2022 61
• FIGURE 27 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY DELIVERY MODE, 2023-2030 (USD THOUSAND) 62
• FIGURE 28 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY DELIVERY MODE, CAGR (2023-2030) 62
• FIGURE 29 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: BY DELIVERY MODE, LIFELINE CURVE 63
• FIGURE 30 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: COMPANY SHARE 2022 (%) 67